Prasugrel
Product Images NDC 50090-5169

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Prasugrel (NDC 50090-5169). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500905169)

Prasugrel 10 mg tablet bottle label from A-S Medication Solutions. The label includes the NDC 50090-5169-0, instructions to store between 68 to 77 degrees Fahrenheit, and indicates the package contains 30 tablets. It also notes that each film-coated tablet contains prasugrel hydrochloride equivalent to 10 mg of prasugrel.*

FDA Label Image

Figure 1 (Prasugrel Fig1)

A Kaplan-Meier curve comparing the percentage of non-CABG-related TIMI major or minor bleeding events over time between Prasugrel and Clopidogrel from randomization up to 450 days. The graph shows Prasugrel with a higher cumulative incidence compared to Clopidogrel. A smaller inset graph displays a similar comparison for the first 7 days post-randomization. Patient numbers at risk for each drug are provided below the x-axis at several time points.*

FDA Label Image

Figure 2 (Prasugrel Fig2)

A line graph depicting the inhibition of platelet aggregation (%) over time (hours) after administration. The graph shows mean values with standard deviation (Mean ± SD) for 20 μM ADP, illustrating inhibition percentage on the y-axis and time in hours on the x-axis, with data points spanning from 0 to 24 hours.*

FDA Label Image

Figure 3 (Prasugrel Fig3)

A Kaplan-Meier curve chart comparing the incidence (%) of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke over days from randomization between Prasugrel and Clopidogrel in patients with UA/NSTEMI. The plot shows a lower event rate for Prasugrel compared to Clopidogrel, with p-values of 0.002 and 0.017 indicated for two time intervals.*

FDA Label Image

Figure 3 (Prasugrel Fig4)

A Kaplan-Meier curve chart depicting cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke rates over days from randomization. It compares Prasugrel and Clopidogrel outcomes in STEMI patients, with Prasugrel showing lower event rates over time. The chart includes a p-value of 0.02, and a smaller inset graph with a p-value of 0.008 comparing the two drugs over a 7-day period.*

FDA Label Image

Figure 4 (Prasugrel Fig5)

A forest plot chart comparing baseline characteristics and percent event rates between Prasugrel and Clopidogrel treatments. It shows hazard ratios with confidence intervals across various subgroups such as age, gender, body weight, region, diabetes status, metabolic syndrome, prior medical history, symptom onset time, stent type, and GP IIb/IIIa inhibitor use. The chart visually indicates relative risk between the two drugs in these categories.*

FDA Label Image

Figure 5 (Prasugrel Fig6)

A forest plot chart titled 'Baseline Characteristics' comparing hazard ratios of Prasugrel versus Clopidogrel across various subgroups including age, gender, body weight, region, diabetes status, metabolic syndrome, previous medical events, symptom onset time, stent type, and inhibitor use. The horizontal axis shows hazard ratio with markers and confidence intervals for each subgroup indicating relative event rates between the two drugs.*

FDA Label Image

Structural Formula (Prasugrel Str)

Chemical structure diagram of Prasugrel hydrochloride, showing its molecular framework including a thiophene ring, fluorophenyl group, and cyclopropyl substituent, with the hydrochloride salt indicated.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.